TABLE 2.
HIV-1 epitopes recognized by study participant CD8+ T cells before and after HIV-1 infection
Participant identifier | Vaccine treatment | Class I HLA type | Days postinfection | Viral load RNA (copies/ml) | HIV-1 epitopei | IFN-γ SFC/ 106 PBMC
|
|
---|---|---|---|---|---|---|---|
Before | After | ||||||
014A-003 | Placebo | A*0101, A*2902; B*1501, B*5701 | 58 | 1,525 | Gag TSTLQEQIGW | <20 | 125 |
014A-006 | Placebo | A*0101; B*0801, B*1401 | 59 | 1,749,235 | Env IVELLGRRGWEVLKY | <20 | 1,790 |
Env RQGLERALL | <20 | 2,835 | |||||
Env ERYLKDQQL | <20 | 2,350 | |||||
Nef FLKEKGGL | <20 | 695 | |||||
Nef AAVDLSHFL | <20 | 2,545 | |||||
402FIEa | Placebo | A3, A32; B38, B64 | 60 | 2,069 | Gag RLRPGGKKK | <20 | 137 |
Gag VDRFYKTLRAEQASQ | <20 | 690 | |||||
Env MHEDIISLW | <20 | 280 | |||||
Vpr GLGQHIYETYGDTWAe | <20 | 260 | |||||
014A-001 | vCP205/gp120 | A*0202, A*8001; B*1801, B*5301 | 64 | NAb | Gag QAISPRTLNAW | <20 | 103 |
Env RIRQGLERA | <20 | 373 | |||||
Nef YPLTFGWCY | <20 | 113 | |||||
014A-004 | vCP205 | A*0201, A*1101; B*4002, B*5101 | 46 | <50 | Pol TAFTIPSI | <20 | 210 |
Gag CTERQANFL | 129 | 70 | |||||
Gag SLYNTVATLh | 47 | 149 | |||||
Nef AVDLSHFLK | 74 | 740 | |||||
014A-005 | vCP205/gp120 | A*2501, A*3002; B*0702, B*1801 | 71 | 65,775 | Gag QAISPRTLNAW | <20 | 358 |
Gag ETINEEAAEW | <20 | 363 | |||||
Env TENFNMWKNNMVEQM | <20 | 585 | |||||
Env IPRRIRQGL | <20 | 943 | |||||
Nef FPVTPQVPLR | <20 | 558 | |||||
Tat CCFHCQVC | <20 | 408 | |||||
Pol QKQGQGQWTYQIYQE | <20 | 165 | |||||
Pol KIQNFRVYY | <20 | 435 | |||||
Vpr EAVRHFPRIWLHGLG | <20 | 490 | |||||
014A-008 | vCP205 | A*0201, A*0301; B*4501, B*5301 | 106 | 130,483 | Gag RLRPGGKKK | <20 | 220 |
014A-009 | vCP205 | A1, A2; B8, B38 | 87 | 12,413 | Gag EIYKRWII | <20 | 290 |
Env MHEDIISLW | <20 | 300 | |||||
Env RRGWEVLKY | <20 | 115 | |||||
Env RQGLERALL | <20 | 240 | |||||
Nef IHSQRRQDILDLWIY | <20 | 125 | |||||
014A-011 | vCP205 | A*0201; B*31012, B*1501 | 122 | <400c | None | ||
40287N | vCP125/gp120 | A1, A33; B8, B44 | 318 | 17,392 | Gag GGKKKYKL | <20 | 570 |
Gag EIYKRWII | <20 | 150 | |||||
Vpr EAVRHFPRIWLHGLG | <20 | 160 | |||||
Vpu EYRKILRQRKIDRLI | <20 | 120 | |||||
402I03f | vCP65/gp120 | A3, A33; B15 (63), B27 | 242 | 2,109 | Gag IRLRPGGKK | <20 | 3,960 |
Gag KRWIILGLNK | <20 | 5,310 | |||||
Gag GLNKIVRMY | <20 | 570 | |||||
Gag MMQRGNFRNQRKIVKe | <20 | 2,510 | |||||
Env SFNCGGEFF | <20 | 750 | |||||
Env LQRAGRAILHIPTRI | <20 | 190 | |||||
402I15 | vCP205 | A1, A10 (26); B8, B17 (57) | 92 | 41,742d | Gag QMVHQAISPRTLNAWe | <20 | 300 |
Rev DEELIRTVRLIKLLYe | <20 | 330 | |||||
Nef FLKEKGGL | <20 | 480 | |||||
403-006 | vCP205/gp160 | A2, A2; B62, B35 | 141 | 3,069 | Gag PPIPVGDIY | <20 | 95 |
Vif DAKLVITTY | <20 | 95 | |||||
2x0226 | vCP205/gp120 | NAb | 30 | NAb | Vif DAKLVITTY | <20 | 2,943 |
Env PIPIHYCAPAGFAIL | <20 | 153 | |||||
203-033 | vCP1452 | A*2501, A*6601; B*0702, B*1801 | 39 | 165,509d | Noneg | ||
203-157 | vCP1452/gp120 | A*3001, A*3002; B*4201/02, B*4403/26/30 | 91 | 32,511d | Pol YPGIKVRQL | NDj | 490 |
Pol KIQNFRVYY | 365 | ||||||
Pol DDTVLEEMSLPGRWK | 215 |
Some responses mapped in this individual at 143 dpi (viral load of <400 and participant on ART).
NA, data not available.
On ART at time of mapping.
No viral load was obtained on the visit date of sample collection. Thus, the closest viral load reported for 402I15 was 3.3 months post-sample date; for 203-033, it was 0.4 months post-sample date; for 203-157, it was 0.7 months post-sample date.
By matrix only. The individual peptide was not tested due to insufficient cells.
Responses to Vif and Vpr peptide pools were not tested in this individual. Pol pools 9 and 10 were also positive, but an exact peptide(s) was not identified due to insufficient cells.
Only a weak PHA response (587 SFC/106 PBMC) was detected at this time point.
See later figures and Discussion.
The vaccine contained the epitopes shown in bold.
ND, not determined.